Likvor first international order

Press release
Stockholm Mars 8, 2010


Likvor first international order

LinkMed's portfolio company Likvor has received its first order for the Likvor
CELDA™ system from a customer outside Sweden. The order comes from Aalborg
Hospital which is the largest hospital in the North Denmark Region. This is the
fifth order for the instrument since it got CE marked in September, 2009.  With
Likvor CELDA™ the clinic will be able to measure the dynamics of the most
important parameters concerning the patients' cerebrospinal fluid including
pressure and flow in a controlled and safe process. Likvor CELDA™ was developed
to facilitate greater understanding and enhance diagnosis of normal pressure
hydrocephalus (NPH), a condition that is often mistaken for dementia. 

Likvor CELDA™ is the first commercially approved instrument for assessing the
flow of CSF fluid that surrounds the brain and spinal cord. It increases the
possibility for patients who suffer from NPH to receive a correct diagnosis and
therefore the appropriate treatment in the form of a shunt implant that diverts
and regulates CSF pressure and flow. An accurate diagnosis means large gains for
the patient and family, but also for society as a whole. 

Likvor CELDA™ is used with a special developed catheter, CELDA TOOLS™ that is a
disposable for one time use only.

Hidden and misdiagnosed disease
Normal Pressure Hydrocephalus (NPH) is a relatively unknown disease that is
often mistakenly diagnosed as dementia, Alzheimer's or Parkinson's. This is
because the symptoms, including disturbances in gait, confusion and urinary
incontinence, are similar to those of dementia, plus that NPH is a condition
that mainly occurs in people over the age of 55. Studies have shown that up to
10 percent of dementia patients may actually be suffering from NPH.

NPH is a condition that is relatively easily treated by the insertion of a
shunt, which helps the patient to regulate CSF flow and pressure. 

Likvor's principal owners are Uminova Invest and LinkMed. For more information
about Likvor, please visit www.likvor.com.

For more information please contact:
Kjell Öberg, CEO Likvor: +46 70 640 14 92
Okee Williams, Portfolio Manager LinkMed: +46 70 600 5364
Agneta Edberg, Head of Sales and Marketing Likvor +46 70 555 7518


LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management and capital, LinkMed has created a
portfolio of thirteen companies, four in drug development and biotechnology and
nine in diagnostics and medical technology. The company's principal shareholders
are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB.
LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section
(ticker: LMED).